ABSTRACT: Thyroid disruption by xenobiotics is associated with a broad spectrum of severe adverse outcomes. One possible molecular target of thyroid hormone disrupting chemicals (THDCs) is transthyretin (TTR), a thyroid hormone transporter in vertebrates. To better understand the interactions between TTR and THDCs, we determined the crystallographic structures of human TTR in complex with perfluorooctanesulfonic acid (PFOS), perfluorooctanoic acid (PFOA), and 2,2′,4,4′-tetrahydroxybenzophenone (BP2). The molecular interactions between the ligands and TTR were further characterized using molecular dynamics simulations. A structure-based virtual screening (VS) protocol was developed with the intention of providing an efficient tool for the discovery of novel TTR-binders from the Tox21 inventory. Among the 192 predicted binders, 12 representatives were selected, and their TTR binding affinities were studied with isothermal titration calorimetry, of which seven compounds had binding affinities between 0.26 and 100 μM. To elucidate structural details in their binding to TTR, crystal structures were determined of TTR in complex with four of the identified compounds including 2,6-dinitro-p-cresol, bisphenol S, clonixin, and triclopyr. The compounds were found to bind in the TTR hormone binding sites as predicted. Our results show that the developed VS protocol is able to successfully identify potential THDCs, and we suggest that it can be used to propose THDCs for future toxicological evaluations.
■ INTRODUCTION
Thyroid hormone disrupting chemicals (THDCs) are anthropogenic compounds that disrupt the homeostasis of the thyroid hormone (TH) system 1 and can induce disorders in physiological processes, including macronutrient metabolism, energy balance, brain development, and reproduction. 2 Exposure to THDCs poses a significant threat to human health, especially during fetal development. Prenatal hypothyroxinemia induced by THDCs can impair the development of the embryonic brain and lead to neurologic deficits such as visuo-spatial processing difficulties 3 and reduced learning and memory. 4 Transthyretin (TTR), a homotetrameric serum protein that transports L-thyroxine (T4), 5 has been suggested to be a possible molecular target of THDCs such as per-and polyfluoroalkyl substances (PFASs) 6 and hydroxylated polychlorinated biphenyls (OH-PCBs).
7 TTR is the primary TH transporter in developing rodents, 8 fish, birds, and amphibians, 9 and THDCs can disrupt TH transport by competitively binding to the two identical thyroxine binding sites (TBSs) situated at the dimeric interface of TTR. 10,11 TTR can also mediate delivery of THDCs across the placental and blood-brain barrier into the fetus and brain.
12−14 Most TTR in human plasma resides in the apo form, and the concentration of tetrameric TTR in plasma (4−7 μM) 15,16 is significantly higher than that of T4 (0.112 μM). 17 This means that low affinity TTR-binders can, without competing with T4, bind to TTR and be transported to vital organs where they may subsequently cause adverse health effects including developmental disorders. 18, 19 Inuit populations that are chronically exposed to relatively high levels of TTR-binding contaminants showed normal T4 levels, but TTR-assisted accumulation of THDCs could potentially cause developmental disorders. 20−22 It is thus critical to understand the molecular interactions between THDCs and TTR and more importantly to identify and reduce the exposure to THDCs that target TTR.
Virtual screening (VS) using molecular docking is an efficient means to reduce costs and animal testing by identifying the most hazardous compounds in risk assessment processes or prioritizing the most promising candidates in drug discovery. 23 , 24 The method has been used to propose novel TTR amyloid inhibitors 25 and to identify environmental pollutants targeting estrogen receptors. 26, 27 Molecular docking can give insights into ligand-protein binding conformations, and this was used to reveal interactions between PFASs and human liver fatty-acid binding proteins. 28 Such studies provide a better understanding of critical molecular interactions between hazardous compounds and their targets.
Crystal structures of ligand-protein complexes are an essential component in the development of VS protocols. Over 200 crystal structures of TTR have been reported in the Protein Data Bank (PDB), 29, 30 but only a few of these are in complex with environmental pollutants or their metabolites. These include TTR complexes with pentabromophenol 31 and OH-PCBs. 10 In addition, we recently determined the crystal structure of TTR with the brominated flame retardant tetrabromobisphenol A (TBBPA). 32 Additional crystal structures of TTR complexes with environmental pollutants with large chemical variation would improve the development of a VS protocol for environmental pollutants and increase our understanding of their interactions with TTR at the molecular level.
In this study, we determined the X-ray structures of human TTR in complex with three emerging contaminants that were shown to bind to TTR: perfluorooctanoic acid (PFOA), perfluorooctanesulfonic acid (PFOS), and 2,2′,4,4′-tetrahydroxybenzophenone (BP2).
6,33 PFOA and PFOS are commonly used as stain, water, and grease repellents in food packaging, carpets, and textiles as well as in fire-fighting foams. 34 BP2 is used as a UV absorber in personal care products and plastic materials. 35 Exposure to PFOS and PFOA is associated with hypothyroidism and an increasing incidence of osteoporosis.
36−38 BP2 might cause the development of endometriosis. 39 These ligands together with TBBPA cover a wide chemical variation of TTR ligands. Their TTR binding activities in human plasma were measured with a previously established plasma assay. 32, 40 The ligand-TTR interactions in the X-ray structures were further studied by performing molecular dynamics (MD) simulations, and residues important for the interactions were proposed by decomposition of ligand-binding free energies using the Molecular Mechanics-Generalized Born Surface Area (MM-GBSA) method. Based on the novel X-ray structures and the molecular interaction information, a structure-based VS protocol was developed to identify THDCs targeting TTR from the Tox21 inventory of 7,849 organic compounds. 41 Twelve representative industrial compounds were selected for in vitro studies using isothermal titration calorimetry (ITC). Of these, four hits have been cocrystallized with TTR to study their binding conformations.
■ MATERIALS AND METHODS
Crystallization of the TTR-THDC Complexes. Human wild-type TTR was purified and crystallized in complex with PFOA, PFOS, BP2, and with four confirmed hits (bisphenol S (BPS), clonixin, 2,6-dinitro-p-cresol (DNPC), and triclopyr) following the procedures described previously. 42, 43 The purified TTR was dialyzed against 10 mM Na-phosphate buffer with 100 mM KCl (pH 7.6) and concentrated to 5 mg/mL using an Amicon Ultra centrifugal filter device (Millipore, 3 kDa molecular-weight cutoff) and cocrystallized at room temperature with a 5-molar excess of the compounds using the vapordiffusion hanging drop method. A drop containing a 3 μL protein solution was mixed with 3 μL of precipitant and equilibrated against a 1 mL reservoir solution containing 1.3− 1.6 M sodium citrate and 3.5% v/v glycerol at pH 5.5 in 24-well Linbro plates. Crystals grew to dimensions of 0.2 × 0.2 × 0.3 mm 3 after 5 days. The crystals were cryoprotected with 12% v/ v glycerol.
Crystallographic Data Collection, Integration, and Structure Determination. The X-ray diffraction data of the complexes were collected at the European Synchrotron Radiation Facility (Grenoble, France) on beamline ID29 or ID23-1 and in-house instruments (Tables S1 and S2 ). The structure of human TTR (PDB ID: 1F41 5 ) and X-ray data from 38.2−2.5 Å resolution were used in molecular replacement searches with the program PHASER. 44 The models were refined against all of the diffraction data using PHENIX. 45 At the end of structure refinement, anisotropic B-factors were refined. Manual map inspection was performed with COOT. 46 The details of the refinement statistics are shown in Tables S1 and S2. Molecular graphics were produced using CCP4 mg. 47 Structure factors and coordinates of the TTR complexes have been deposited with the Protein Data Bank (PDB ID: 5JID (PFOA), 5JIM (PFOS), 5JIQ (BP2), 5L4F (DNPC), 5L4I (clonixin), 5L4J (BPS), and 5L4M (triclopyr)).
Molecular Dynamics Simulations. The MD simulations were prepared based on the three structures of TTR complexes with BP2, PFOA (sharing similar binding profiles with PFOS), and TBBPA. 32 Each system was prepared following the procedures described in the Supporting Information. The MD simulations of each prepared system were performed using Amber 14 48 with the following steps: 1) each system was minimized with two-stage energy minimizations, 2) each system was gradually heated to 310 K and then equilibrated under NPT conditions for 1 ns, and 3) the 20 ns production MD was performed under NPT conditions using a Langevin thermostat and Berendsen barostat. Details of the simulation are described in the Supporting Information.
MM-GBSA Free-Energy Decomposition. We calculated the binding free energies of BP2, PFOA, and TBBPA to TTR using the MM-GBSA method in AmberTools 15 48 based on the last 10 ns of the MD trajectory. The contributions of each residue in the TBS to the ligand binding were determined by the pairwise decomposition method. The five residues that contributed the most to the enthalpic binding free energy of each ligand were considered to be important for ligand-TTR interactions (Table S3 ). The entropy contributions were neglected due to low prediction accuracy. 49 The procedures and parameters are described in the Supporting Information.
Collection and Preparation of the Ligand Data Set. Two ligand sets were used in the study − the TTR benchmarking set and the Tox21 inventory. 41 The TTR benchmarking set (Table S4 ) contained 155 TTR-binders and 10,197 in silico generated decoys (inactives). 50 The TTRbinders were collected from the scientific literature using an activity cutoff of K i or IC 50 ≤ 100 μM as suggested by the US EPA in the studies of THDCs 51 and estrogen disruptors 26, 52 and used in the Tox21Challenge in silico model-developing exercise (more explanations given in the Supporting Information). 53 The benchmarking set was used in the development and evaluation of the VS protocol. The Tox21 data set contains 7,849 industrial compounds and pharmaceuticals. 54 For each compound in the two sets, a maximum of 32 low-energy conformations were generated by considering all chiral atoms using the Schrodinger LigPrep module under the OPLS_2005 force field, 55 and their ionization and tautomeric states were determined at pH 7.0 ± 1.0.
Molecular Docking. Molecular docking models were developed using the TTR complex structures with BP2,
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Article PFOA, and TBBPA. The TBS situated at the BB′ interface was described by a grid box centered on its coligand. The prepared compounds in the TTR benchmarking set were docked into each structure using the Schrodinger Glide module under standard precision. 56 For the docking results, we assessed their VS performance and enrichment. The VS performance of each model was described with the area under curve (AUC) value of the receiver operating characteristic (ROC) curves. The AUC value was used because it is insensitive to the ratio of actives versus decoys in the benchmarking set. 57 The enrichment was characterized by two enrichment factors (EFs) that were evaluated at 10% and 20% of the ranked database, referred to as EF10% and EF20%, respectively. The AUC values and EFs are given in Table S5 .
Ligand-TTR Interaction Analysis. Residues important for ligand-TTR interactions were identified using the MM-GBSA binding free-energy decomposition. The W188 water molecule in the TTR-TBBPA complex was also considered because it was suggested to be critical for mediating hydrogen bonds (Hbonds) between TBBPA and Ser117. 32 For each initial hit identified by molecular docking, we counted the number of electrostatic interactions (H-bonds and salt bridges) with polar residues (including W188) and hydrophobic interactions with nonpolar residues based on their docking poses. The number of interactions together with the docking score was used to refine the initial hits and identify the bioactive compounds from the Tox21 inventory. The refined hits and their interactions with TTR are shown in Table S6 . The known TTR-binders identified among the refined hits are given in Table S7 .
Measuring Compound Binding Activity in Human Plasma. Binding activity of BP2, PFOS, and PFOA to TTR in the presence of human plasma was measured with a previously established plasma assay. 40 Details of experimental procedures are given in the Supporting Information.
Isothermal Titration Calorimetry. The binding affinities of 12 selected potential TTR-binders were measured using an Auto-iTC200 (MicroCal, Malvern, UK) at 25°C. The chemical information and properties of the 12 compounds are shown in Table S8 . Stock solutions were prepared in dimethyl sulfoxide (DMSO) and diluted with phosphate-buffered saline (PBS, pH = 7.4) to a final level of 5% DMSO immediately before the ITC experiments. 40 Aliquots of each compound were titrated into the TTR buffer solution (30 or 90 μM) to reach a 10-fold molar excess. For the control experiment, the compounds were titrated into the cell with only buffer. Raw data were collected, subtracted for compound heats of dilution, and processed using the MicroCal Origin software. Calorimetric data (Table S9) were plotted and fitted using the standard single-site binding model to yield the binding affinities (K d ), enthalpy changes, and entropy changes.
■ RESULTS AND DISCUSSION
Crystal Structures of the TTR-THDC Complexes. We cocrystallized human wild-type TTR in complex with PFOA, PFOS, and BP2 and determined their structures at 1.2−1.4 Å resolution (Table S1 ). The structures showed that all three 
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Article ligands bind at the deep end of the TBS (Figure 1) . Compared with T4, the three ligands have the ability to bind deeper in the pocket due to their smaller molecular size ( Figure S1 ).
Of particular interest are the TTR complex structures with PFOA and PFOS. The structures share three unique features. 1) The two ligands bind with their hydrophobic tail inside the pocket, and their hydrophilic acid groups are surface exposed ( Figure S2 ), which is different from our previous assumption. 33 2) The hydrophobic tail bends at the second to last carbon atom of the ligand to accommodate the volume between two Ser117 residues and to allow the acid groups to form salt bridges with Lys15.
3) The bent hydrophobic tail forces the hydroxyl groups on Ser117 to rotate away from the ligands (Figure 1 ), which creates a more hydrophobic pocket that favors the ligand-TTR interactions.
BP2 interacts with TTR similarly as luteolin in the deep end of the TBS ( Figure S2 ). 58 Two hydroxyl groups form hydrogen bonds with Ser117 residues, and the carbonyl group interacts with Thr119. Interactions between the aromatic ring of BP2 and TTR involve van der Waal contacts with the side chain of Leu17.
MD Simulations for Ligand-TTR Interaction Studies. We investigated the molecular interactions between TTR and THDCs by performing MD simulations on the TTR complex structures with BP2, PFOA, and TBBPA. 32 All three ligands remained bound in the TBS, and the root-mean-squareddeviation (RMSD) of the protein and ligands was under 2 Å throughout the simulations ( Figure S3 and Figure S4 ).
The ligand-TTR binding free energies were calculated using the MM-GBSA method based on the last 10 ns of the MD trajectory. The calculated energies of the ligands correlate well with their previously measured potencies ( Figure S5 ).
6,33,59
The energies were further decomposed to reveal five residues of significance for the ligand-TTR interactions in each of the three complex structures (Table S3) . Two types of ligand-TTR interactions were identified electrostatic interactions with the polar residues B-Thr119, B-Ser117, B′-Ser117, B-Lys15, and B′-Lys15 and hydrophobic interactions with the nonpolar residues B-Leu110, B-Leu17, B′-Leu17, and B-Ala108. The electrostatic interactions account for specific ligand-TTR recognition and a large proportion of the binding free energies, 60−62 whereas the hydrophobic interactions were less significant for ligand binding. The results also revealed that the three ligands interact with the residues deeper in the TBS, e.g. Ser117, whereas T4 interacts with residues at the opening of the TBS, e.g. Glu54. 63 Information on the molecular interactions with the identified residues (Table S3 ) was used to better understand the ligand-TTR interaction and to refine potential TTR-binders for better identifying of bioactive compounds.
Molecular Docking Model. The accuracy of the molecular docking using Glide was assessed by comparing the docking conformations of BP2, PFOA, and TBBPA with their X-ray structures. 33 The RMSD values for the coligands were lower than 2 Å (Table S5 ), indicating that the molecular docking was able to reproduce the actual binding conformation. The prepared compounds in the benchmarking set were docked into each TTR complex, and the docking results were compared in terms of AUC values and enrichment factors (Table S5 ). The TTR-TBBPA structure showed the best results with AUC of 0.75 and good early enrichment (EF10% = 3.76 and EF20% = 2.95), and 141 binders were identified among the 155 binders in the benchmark set (Table S5 ). The docking models based on the TTR-PFOA and TTR-BP2 structures had lower performances in identifying TTR-binders, probably because TBBPA best reflects the majority of the halogenated and hydroxylated aromatic compounds in the benchmark set. However, the two structures provide useful information for molecular interaction studies, and the TTR-PFOA structure reveals the correct binding orientations of PFASs in the TBS where the acidic group was found to interact with Lys15 rather than Ser117.
The impact of water in the TBS of the TTR-TBBPA complex was studied by evaluating the model performance of the structure with and without water molecules in the TBS. The structure with water in the TBS outperformed the one without (Table S5 and Figure S6) . After examining the ligand-protein interactions in the TTR-TBBPA structure, the W188 water molecule was found to be critical for mediating hydrogen bonds between the ligand and the Ser117 residues, which agrees well with previously reported data. 32 Binding Activity of the Studied THDCs to TTR in Human Plasma. We compared the binding activity of BP2, PFOA, and PFOS to TTR in human plasma in terms of their inhibitory concentrations at 50% (IC 50 ) to prevent tetrameric dissociation in the established assay. 32, 40 BP2 bound strongly to TTR with an IC 50 of 4 μM, while PFOA (IC 50 = 175 μM) and PFOS (IC 50 = 103 μM) had poor binding activity to TTR in plasma ( Figure S7 ). Their differences in binding activity could be caused by the hydrophobic tails of the PFASs giving limited electrostatic contributions to their TTR binding, which are critical for molecular recognition. 40, 62 TBBPA has also shown strong binding to TTR (IC 50 = 3.3 μM). 32 Clearly, BP2 share characteristics with TBBPA in terms of molecular interactions with TTR. It is thus of interest to identify contaminants sharing similar molecular interactions with TTR as found in BP2 and TBBPA.
Virtual Screening of Industrial Compounds. The docking model developed using the TTR-TBBPA structure was used as the basis for the VS of the Tox21 inventory because of its high VS performance and the strong binding of TBBPA to TTR in human plasma. We applied a two-step procedure to identify potential TTR-binders from the Tox21 inventory. In the first step, compounds were docked into the TTR-TBBPA structure followed by ranking based on their standard precision docking score. For each industrial compound, all protonation states in the range of pH 7.0 ± 1.0 were considered during the molecular docking. As suggested by previous studies, 64, 65 we selected its top scored protonation form (Tables S4 and S6) , since docking score considers both binding affinity and tautomeric ratio. 66, 67 The top 20% scored compounds covering 1,282 hits were considered as initial hits for TTR, and these were extracted for further analysis. In the second step, the initial hits were further refined by selecting those that showed at least three electrostatic interactions with the identified polar residues (including W188) and two hydrophobic interactions with the nonpolar residues. The criteria were based on the interactions between TTR and TBBPA that binds to TTR with a K d of 20 nM. 32 The electrostatic interactions have been suggested to be critical for specific recognition of TTR. 60−62 A total of 192 substances among the top 20% scored compounds also fulfilled the molecular interaction criteria (Table S6 ) and thus were predicted to be potential TTR binders by the VS protocol. Eleven known TTR-binders were identified (Table S7) , including five pharmaceuticals (including diflunisal and aceclofenac), 40 two flame retardants (TBBPA and tetrachlorobisphenol A), one herbicide (2,4,5-trichlorophenoxyacetic acid
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Article (2,4,5-T)), 33 one UV filter BP2, and one T4 derivative (3,3′,5,5′-tetraiodothyroacetic acid). 68 The recognition of these known TTR binders by the VS protocol indicates that it is capable of identifying potential TTR-binders for further toxicological investigations.
Binding Affinities of Selected Compounds. We selected 12 representative compounds (Table 1) for in vitro validation from the VS results based on their various applications, structural diversity, and environmental relevance. These compounds mainly represent herbicides and polymer additives (plasticizers and polymerization inhibitors) and include primarily halogenated and/or aromatic substances as well as nitro compounds. The thermodynamic profiles of the ligand-TTR binding were investigated using ITC (Figure 2) . One TTR tetramer can bind two ligands. However, we fitted ITC thermograms (Figure 2 ) using a one-site binding model as binding of the first ligand dominates the total binding energy and its affinity is approximately 100 times stronger than the second ligand. 69, 70 The ITC results showed that seven of the 12 compounds bound to TTR with K d values below 100 μM (Table 1) indicating that our VS protocol gave a reasonable hit rate of approximately 60%, which can be compared with commonly practiced VS campaigns that generally have a hit rate of 20−40%. 71, 72 The thermodynamic data (Table S9) revealed that the binding of BPS, clonixin, fluroxypyr, mesotrione, and triclopyr was largely driven by the enthalpic component, whereas the binding energy of DNPC and picloram was mainly entropy driven. The affinities of the active compounds were not correlated with their docking scores ( Figure S8 ), which was not surprising since docking scores generally give poor estimations of the binding affinities. 73, 74 However, the trend is correct (except DNPC), as more negative docking scores are associated with higher affinities. Notably, five predicted binders showed no activities in the ITC experiments ( Figure S9) , and we provide a thorough discussion on the potential reasons for their mispredictions in the Supporting Information.
Crystal Structures of the TTR-Confirmed Hits Complexes. Four confirmed TTR-binders (clonixin, DNPC, triclopyr, and BPS) were selected for cocrystallization with human wild-type TTR, considering their high binding affinities, diverse structures, and various applications. The crystal structures were determined at 1.5−1.6 Å resolution (Table  S2) . Compared with T4, the four ligands bind deeper in the TBS due to their smaller molecular size (Figure 3 ). Clonixin interacts with TTR similarly as flufenamic acid. 75 It forms Hbonds and salt bridges with Lys15 ( Figure S10 ). DNPC presents different binding conformations in the two TBSs. Furthermore, in the AA′ interface, two DNPC molecules bind into the TBS simultaneously where one DNPC interacts with Ser117 at the deep end of TBS, whereas the other DNPC binds to Lys15 at the cavity entrance ( Figure S10 ). In the BB′ interface, DNPC also binds in two different orientations; however, these conformations are different from the ones in AA′, and both cannot be occupied at the same time as their binding sites overlap (Figure 3) . The multiple conformations of DNPC give better knowledge on interactions between TTR and nitro compounds, which provides guidance for molecular design and risk assessment. Triclopyr interacts with TTR by having electrostatic interactions with Lys15. BPS binds in the TBS similarly as TBBPA. 32 Its hydroxyl groups interact with Lys15 and form water-bridged H-bonds with Thr119 and Ser117 ( Figure S8) . We compared the docking pose of each ligand with its crystal conformation in the BB′ interface ( Figure  S11 ), and the results showed that we correctly predicted the binding conformations for clonixin, DNPC, and triclopyr. The inaccurate prediction of BPS may be due to its weaker affinity and high mobility in the TBS. Besides DNPC, EMD21388 was also reported to adapt to distinctive binding-modes in the two TBSs. 76 Ensemble docking has been proposed as a suitable strategy for predicting conformation of such ligands, 77,78 which however was not completed here due to lack of TTR structures with similar binding-modes to DNPC.
Environmental Implications of the Potential THDCs. Seven compounds with diverse structures and various applications were identified as TTR-binders (Table 1) . These compounds warrant further toxicological investigations considering the following two reasons: (1) humans may be chronically exposed to the compounds at doses that are similar or significantly higher than the normal T4 level (0.112 μM). 17 In vivo levels of the compounds have been reported to be 35844 μM (9.416 mg/mL) for clonixin, 79 0.312 μM (0.08 μg/mL) for triclopyr, 80 3.72 μM (0.93 μg/mL) for BPS, 81 and 9.19 μM (2.22 μg/mL) for picloram. 82 (2) Low-affinity binders could be effectively transported by TTR and accumulated in vulnerable organs in vivo, 12−14 since most TTR in human plasma resides in the apo form.
15−17 Their accumulations could subsequently induce adverse effects including developmental disorders. 18, 19 
Article Interestingly, BPS, a replacement for bisphenol A (BPA), bound to TTR with a K d of 52 μM. BPS is used extensively as a plasticizer in BPA-free consumer products and as an anticorrosive agent in canned food. Despite claims that it is a safer alternative to BPA, BPS has been reported to pose similar potential health hazards as BPA in a number of in vitro and in vivo studies. 83 Embryonic exposure to BPS is associated with neurogenesis within the hypothalamus, causing gestation and hyperactivity in juvenile zebrafish 84 and nonassociative learning impairments in adult zebrafish. 85 BPS can also decrease plasma TH levels and impair the reproductive potential of zebrafish. 86 It was also found in dust samples in 12 countries, and the highest median concentration was in Greece (860 ng/g). 87 Clonixin was the strongest TTR binder identified in the Tox21 inventory and had a K d of 0.26 μM. Clonixin is a nonsteroidal anti-inflammatory drug, and it has a similar structure and TTR binding affinity as meclofenamic acid. 40 To our knowledge, its thyroid effects have not been studied.
DNPC is used as an inhibitor of styrene polymerization and a dye intermediate, and this molecule showed the second strongest interaction with TTR. DNPC is an uncoupler of oxidative phosphorylation in humans, and it can cause acute hyperthermia, kidney and liver failure, and cerebral edema. 88 DNPC has a high potential for accumulation in biota and humans. 88 The herbicides fluroxypyr, mesotrione, picloram, and triclopyr were identified as TTR-binders, with triclopyr being the strongest binder. Triclopyr is used as an alternative to 2,4,5-T, and it has been reported to cause thyroid-related neurotoxicity 89 and developmental toxicity in rats. 90 The major metabolite of triclopyr is 3,5,6-trichloro-2-pyridinol, 91 which is also a TTR-binder, 33 and it has been reported to disrupt the levels of T4 and thyroid stimulating hormone in humans. 92 Exposure to triclopyr poses a significant threat to its applicators, and the amount in their urine samples was reported to be 1−13 mg/day. 93 The compound has been detected in water samples from Australia, 94 France, 95 and multiple locations in the US. 96, 97 Environmental implications of the other three herbicides are given in the Supporting Information.
In summary, we have determined the binding conformations of PFOS, PFOA, and BP2 in the TBS of TTR. The structures of the complexes provide valuable information for improving our understanding of the molecular interactions between TTR and emerging contaminants. PFOS and PFOA were previously reported as strong TTR-binders, but our results indicate that they are weak binders in plasma, whereas BP2 showed strong binding activity. BP2 is thus more likely to be transported by TTR and accumulated in vulnerable organs. Based on the novel TTR complex structures and the information on molecular interactions obtained from MD simulations, a VS protocol was developed for the identification of potential THDCs targeting TTR from the Tox21 inventory. The protocol proposed 192 industrial compounds as potential binders to TTR. Among the 12 compounds tested using in vitro experiments, we identified seven novel TTR-binders including clonixin, DNPC, triclopyr, fluroxypyr, BPS, picloram, and mesotrione. Most of these have been detected in the environment and have shown adverse thyroid-related effects in animal models. We further cocrystallized TTR with PBS, clonixin, DNPC, and triclopyr, and their structures showed that the compounds bind in the TBS as predicted by the VS protocol. We suggest further in vivo studies on these TTR-targeting compounds especially as they may accumulate in vulnerable organs. ■ REFERENCES 
